Literature DB >> 19885123

Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics.

Daniel E Levy1.   

Abstract

Type 2 diabetes constitutes a major health risk in the United States, with over 20% of individuals over the age of 60 currently suffering from this disease and an additional 1.5 million new cases diagnosed in patients over 20 years of age in 2005. Similarly, Alzheimer's disease represents a major risk to the aging population, with recent statistics estimating up to 16 million people diagnosed by 2050 in the United States alone. As type 2 diabetes and Alzheimer's disease are now recognized as members of the broader class of amyloid diseases and because the pathologies of disease progression between these indications is similar, common strategies focused on the design of next-generation therapeutics can be envisioned and are discussed herein.

Entities:  

Keywords:  Alzheimer's; amyloid; diabetes; insulin; islet; neuronal; pancreatic; plaques

Year:  2007        PMID: 19885123      PMCID: PMC2769628          DOI: 10.1177/193229680700100418

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  23 in total

1.  Amyloidosis: a convoluted story.

Authors:  R A Kyle
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

2.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.

Authors:  Enrique J Rivera; Alison Goldin; Noah Fulmer; Rose Tavares; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2005-12       Impact factor: 4.472

Review 3.  Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease.

Authors:  Mary N Haan
Journal:  Nat Clin Pract Neurol       Date:  2006-03

Review 4.  The cholinergic hypothesis--ten years on.

Authors:  E K Perry
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

5.  Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.

Authors:  Minji Kim; Louis B Hersh; Malcolm A Leissring; Martin Ingelsson; Toshifumi Matsui; Wesley Farris; Alice Lu; Bradley T Hyman; Dennis J Selkoe; Lars Bertram; Rudolph E Tanzi
Journal:  J Biol Chem       Date:  2007-01-22       Impact factor: 5.157

6.  Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets.

Authors:  J F Paulsson; A Andersson; P Westermark; G T Westermark
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

7.  The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration.

Authors:  So-Young Park; Adriana Ferreira
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

Review 8.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

Authors:  Suzanne Craft
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

Review 9.  Amyloidosis and the heart: a comprehensive review.

Authors:  Keyur B Shah; Yoshio Inoue; Mandeep R Mehra
Journal:  Arch Intern Med       Date:  2006-09-25

10.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.